miR-425-5p suppresses tumorigenesis and DDP resistance in human-prostate cancer by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway
Authors:
- 9 August 2019
- journal article
- review article
- Published by Springer Nature in Journal of Biosciences
- Vol. 44 (4) , 102
Abstract
Prostate cancer (PCa) represents the most frequently diagnosed cancer in men. Cisplatin, also known as cis-diamminedichloroplatinum (DDP), is a standard chemotherapeutic agent used to treat PCa, and DDP resistance remains one important obstacle in DDP-based chemotherapy. In our research, we found miR-425-5p was down-regulated in PCa and even lower in DDP-resistant PCa determined by quantitative polymerase chain reaction; in contrast, GSK3β mRNA expression was upregulated in PCa and even higher in DDP-resistant PCa. Moreover, there was a modest but significant inverse correlation between the expression of GSK3β mRNA and miR-425-5p. Functional experiments showed that miR-425-5p mimic inhibited DDP resistance as evidenced by a promoted apoptosis rate (flow cytometry) and suppressed cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay) and expressions of MDR1 and MRP1 (western blotting) in DU145/DDP and PC3/DDP cells. Luciferase reporter assay and RNA immunoprecipitation identified GSK3β was a potential target of miR-425-5p. The effect of miR-425-5p mimic on DDP resistance was partially reversed by pcDNA-GSK3β. Mechanically, miR-425-5p mimic reduced expression of β-catenin, cyclin D1 and C-myc, which was further blocked when GSK3β overexpressed. In vivo experiments, recovery of GSK3β prevented xenograft tumor growth and DDP resistance in the presence of miR-425-5p mimic. To sum up, miR-425-5p upregulation might sensitize human PCa to DDP by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway.Keywords
This publication has 39 references indexed in Scilit:
- Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancerBMC Genomics, 2013
- MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancerInternational Journal of Oncology, 2013
- Therapeutic Potential of an Anti-diabetic Drug, Metformin: Alteration of miRNA expression in Prostate Cancer CellsAsian Pacific Journal of Cancer Prevention, 2013
- Relationship between multidrug resistance 1 polymorphisms and the risk of prostate cancer in Chinese populationsGenetics and Molecular Research, 2013
- Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancerInternational Journal of Cancer, 2012
- miR-21: an oncomir on strike in prostate cancerMolecular Cancer, 2010
- Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugsThe Prostate, 2009
- Mechanism of multidrug recognition by MDR1/ABCB1Cancer Science, 2007
- Role of the MRP1/ABCC1 Multidrug Transporter Protein in CancerIUBMB Life, 2007
- Inactivation of Nuclear Factor κB by Soy Isoflavone Genistein Contributes to Increased Apoptosis Induced by Chemotherapeutic Agents in Human Cancer CellsCancer Research, 2005